In situ—forming biodegradable polymeric systems loaded with betamethasone (BTM) and betamethasone acetate (BTMA) (5, 7, and 10% (w/w)) were prepared using poly(DL-lactide-co-glycolide) (33% (w/w)), ethyl heptanoate (5% (w/w)), and N-methyl-2-pyrrolidone as biodegradable material, additive, and solvent, respectively. The effects of gamma irradiation, drug loading, and solvent removal on release profiles were evaluated. The drug release in phosphate-buffered solution (pH = 7.4, 37°C) was measured using high-performance liquid chromatography. The release profiles of irradiated and nonirradiated formulations based on BTMA showed a three-phase release pattern, whereas the pattern for BTM was biphasic. Gamma irradiation had no significant effect on the BTMA release profiles ( p>0.05). Unexpectedly, irradiation had a significant effect on release behavior of BTM ( p<0.05); also, the rate of BTM release was decreased with an increase in drug loading up to 10%. The amount of BTM that was released in the burst phase decreased by about 1.4 and 1.5 times for 7 and 10% BTM loading, respectively. The duration of BTM release was more than that of BTMA. Changes in hydrophobicity and hydrogen bonding had a strong effect on the release behavior of the two forms of BTM from the in situ—forming systems.
Parfitt, K. (1999). Martindale: The Complete Drug Reference, 39th edn, p. 1033, Pharmaceutical Press, Taunton, MA.
2.
Smith, S.J. and Bernstein, J.A. (1996). Therapeutic Uses of Lung Aerosols. In: Inhalation Aerosols, Hickey, A.J. (ed.), p. 231, Marcel Dekker, New York.
3.
Fresta, M. and Puglisi, G. (1997). Corticosteroid Dermal Delivery with Skin-Lipid Liposomes. J. Control. Release, 44(2—3): 141—151.
4.
Reddy, K.R. (2000). Controlled Release, Pegylation, Liposomal Formations: New Mechanisms in the Delivery of Injectable Drugs. Ann. Pharmacother. , 34(7—8): 915—922.
5.
Arthur, J.T. and Richard, L.D. (2000). In Situ Gelling Formulations. In: Sustained-Release Injectable Products, Senior, J.H. and Radomsky, M. (eds), p. 241, Interpharm Press, Inc., Buffalo Grove, IL.
6.
Eliaz, R.E. and Kost, J. (2000). Characterization of a Polymeric PLGA-injectable Implant Delivery System for the Controlled Release of Proteins. J. Biomed. Mater. Res., 50: 388—396.
7.
Jeong, B., Bae, Y.H. and Kim, S.W. (2000). In-situ Gelation of PEG-PLGAPEG Triblock Copolymer Aqueous Solutions and Degradation Thereof. J. Biomed. Mater. Res., 50: 171—177.
8.
Hatefi, A. and Amsden, B. (2002). Biodegradable Injectable in situ Forming Drug Delivery Systems. J. Control. Release, 80(1—3): 9—28.
9.
Zhu, H., Wu, Q., Shentu, J., Wang, H., Hu, Y., Zhu, K. and Liu, J. ( 2005). Release Behavior and Biological Activity of Recombinant Human Bone Morphogenetic Protein-2 from Porous PLGA Scaffold. J. Bioact. Compat. Polym., 20: 271—278.
10.
Thatte, S., Datar, K. and Ottenbrite, R.M. (2005). Perspectives on: Polymeric Drugs and Drug Delivery SystemsJ. Bioact. Compat. Polym. , 20: 585—601.
11.
Pan, G., Lemmouchi, Y., Akala, E. and Bakare, O. (2005). Studies on PEGylated and Drug-Loaded PAMAM Dendrimers . J. Bioact. Compat. Polym., 20: 113—128.
12.
Chiellini, F. (2006). Perspectives on: in vitro Evaluation of Biomedical Polymers. J. Bioact. Compat. Polym. , 21: 257—271.
13.
Jain, R.A., Rhodes, C.T., Railkar, A.M., Malick, A.W. and Shah, N.H. (2000).Controlled Delivery of Drugs from a Novel Injectable in situ Forming Biodegradable PLGA Microsphere System. J. Microencapsul., 17(3): 343—362.
14.
Kimura, H. and Ogura, Y. (2001). Biodegradable Polymers for Ocular Drug Delivery . Ophthalmologica, 215(3): 143—155.
15.
Richard, L. (2006). Emulsions for in-situ delivery systems. United States Patent No. 7,128,927.
16.
Packhaeuser, C.B., Schnieders, J., Oster, C.G. and Kissel, T. (2004). In Situ Forming Parenteral Drug Delivery Systems: An Overview. Eur. J. Pharm. Biopharm. , 58(2): 445—455.
17.
EAFUS: A Food Additive Database. (2006). October 23. Available from: http://vm.cfsan.fda.gov/∼dms/eafus.html .
18.
Bakhshi, R. , Vasheghani-Farahani , E., Mobedi, H., Jamshidi, A. and Khakpour, M. (2006). The Effect of Additives on Naltrexone Hydrochloride Release and Solvent Removal Rate from an Injectable in situ Forming PLGA Implant. Polym. Adv. Technol., 17(5): 354—359.
19.
Graham, P.D. , Brodback, K.J. and McHugh, A.J. (1999). Phase Inversion Dynamics of PLGA Solutions Related to Drug Delivery. J. Control. Release , 58(2): 233—245.
20.
Brodbeck, K.J. , Desnoyer, J.R. and McHugh, A.J. (1999). Phase Inversion Dynamics of PLGA Solutions Related to Drug Delivery. Part II. The Role of Solution Thermodynamics and bath-side mass transfer. J. Control. Release , 62(3): 333—344.
21.
Dong, W.Y., Körber, M., López Esguerra, V. and Bodmeier, R. (2006). Stability of Poly(DL-lactide-co-glycolide) and Leuprolide Acetate in in-situ Forming Drug Delivery Systems. J. Control. Release, 115(2): 158—167.
22.
Martínez-Sancho, C., Herrero-Vanrell , R. and Negro, S. (2004). Study of Gamma-Irradiation Effects on Acyclovir Poly(DL-lactic-co-glycolic) Acid Microspheres for Intravitreal Administration. J. Control. Release, 99(1): 41—52.
23.
Eliaz, R.E., Wallach, D. and Kost, J. (2000). Delivery of Soluble Tumor Necrosis Factor Receptor from in Situ Forming PLGA Implants: in-vivo. Pharma. Res., 17(12): 1546—1550.
24.
Matschke, C., Jsele, U., Hoogevest, P.V. and Farh, A. (2002). Sustained-Release Injectable Formed in situ and Their Potential use for Veterinary Products. J. Control. Release , 85(1—3): 1—15.
25.
Yoshioka, S. , Aso, Y., Otsuka, T. and Kojima, S. (1995). The Effect of Irradiation on Drug Release from Poly(lactide) Microspheres. Radiat. Phys. Chem., 46(2): 281—285.
26.
Lee, T.H., Wang, J. and Wang, C.H. (2002). Double-Walled Microspheres for the Sustained Release of a Highly Water Soluble Drug: Characterization and Irradiation Studies. J. Control. Release, 83(3): 437—452.
27.
Montanari, L., Costantini, M., Signoretti, E.C., Valvo, L., Santucci, M., Bartolomei, M., Fattibene, P., Onori, S., Faucitano, A., Conti, B. and Genta, I. (1998). Gamma Irradiation Effects on Poly(DL-Lactictide-coglycolide) Microspheres. J. Control. Release, 56(1—3): 219—229.
28.
Astaneh, R. , Moghimi, H.R., Erfan, M. and Mobedi, H. (2006). Formulation of an Injectable Implant for Peptide Delivery and Mechanistic Study of the Effect of Polymer Molecular Weight on its Release Behavior. DARU, 14(2): 65—70.
29.
Shaha, N.H. , Railkar, A.S., Chen, F.C., Tarantino, R., Kumar, S., Murjani, M., Palmer, D., Infeld, M.H. and Malick, A.W. (1993). A Biodegradable Injectable Implant for Delivering Micro and Macromolecules Using Poly(lactic-co-glycolic) Acid Copolymer. J. Control. Release, 27(2): 139—147.
30.
Mathiowitz, E. (1999). Biodegradable Polymers . In: Encyclopedia of Controlled Drug Delivery, p. 71, John Wiley, New York.
31.
Lu, L., Peter, S.J., Lyman, M.D., Lai, H.L., Leite, S.M., Tamada, J.A., Uyama, S., Vacanti, J.P., Langer, R. and Mikos, A.G. (2000). In vitro and in vivo Degradation of Porous Poly(DL-Lactic-Co-Glycolic Acid) Foams. Biomaterials, 21(18): 1837—1845.
